t-PA


Also found in: Dictionary, Medical, Encyclopedia.
Related to t-PA: urokinase, heparin
AcronymDefinition
t-PATissue Plasminogen Activator
References in periodicals archive ?
t-PA antigen in endothelial cell-CM was determined by two-site, 'sandwich'-specific, commercially available enzyme-linked immunosorbent assays (ELISA) (Technoclone, Austria) according to manufacturer's instructions.
Alexandrov believes that the combined treatment works because ultrasound is causing a gentle mechanical pressure wave, which delivers more t-PA molecules to and through the clot.
While the NINDS study (2) established that IV t-PA was useful if given to patients with nonhemorrhagic stroke within 3 hours of symptom onset regardless of associated parenchymal ischemic changes, the European Cooperative Acute Stroke Study (ECASS) trial (10) studied patients with stroke symptoms of <6 hours' duration who had CT-demonstrable ischemic changes involving no more than one third of the MCA territory.
of t-PA. Binds with plasminogen inside the clot and converts it to plasmin.
They were treated with escalating doses of 0.5 mg/mL, 1.0 mg/mL, and 2 mg/mL of t-PA. It was determined that 50 (85%) of the occluded catheters cleared with 0.5 mg/mL.
Doctors at OHSU's Oregon Stroke Center have been testing one of those devices, developed by a Bothell, Wash., company, that simultaneously delivers t-PA and ultrasound waves to break up a stroke-inducing clot.
Q: It seems that the problem in many emergency rooms is that the time between diagnosing the stroke and administering the t-PA often extends beyond the critical window of opportunity.
Marler notes that the researchers also confirmed suspicions that t-PA increases a person's risk of having a serious brain hemorrhage.
By studying 631 male physicians randomly selected from a larger health study, the researchers found an association between moderate alcohol consumption and the body's production of t-PA antigen, which plays a central role in preventing thrombosis, or chronic internal blood clotting.
The key element in such genetic modifications is the gene for the anti-clotting substance t-PA (tissue plasminogen activator) specially configured so that it would be secreted at levels potentially high enough to prevent clot formation inside a blood vessel graft.
Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
Patients who are ineligible for intravenous tissue plasminogen activator or who fail IV t-PA therapy are candidates for treatment.